Malignant gliomas are highly dependent on the isoprenoid pathway for the synthesis of lipid moieties critical for cell proliferation. The isoprenoid derivative N6-isopentenyladenosine (iPA) displays pleiotropic biological effects, including a direct antitumor activity in several tumor models. The antiglioma effects of iPA was then explored in U87MG cells both in vitro and grafted in mice and the related molecular mechanism confirmed in primary derived patients' glioma cells. iPA powerfully inhibited tumor cell growth and induced caspase-dependent apoptosis through a mechanism involving a marked accumulation of the pro-apoptotic BIM protein and inhibition of EGFR. Indeed, activating AMPK following conversion into its iPAMP active form, iPA stimulated EGFR phosphorylation and ubiquitination along a proteasome-mediated pathway which was responsible for receptor degradation and its downstream signaling pathways inhibition, including the STAT3, ERK and AKT cascade. The inhibition of AMPK by compound C prevented iPA-mediated phosphorylation of EGFR, known to precede receptor loss. As expected the block of EGFR degradation, by exposure to the proteasome inhibitor MG132, significantly reduced iPA-induced cell death. Given the importance of receptor degradation in iPA-mediated cytotoxicity, we also documented that the EGFR expression levels in a panel of primary glioma cells confers them a high sensitivity to iPA treatment. In conclusion our study provides the first evidence of iPA antiglioma effect. Indeed, as glioma is driven by aberrant signaling of growth factor receptors, particularly the EGFR, iPA, alone or in association with EGFR targeted therapies, might be a promising therapeutic tool to achieve a potent anti-tumoral effect.
Malignant glioma of astrocytic origin (astrocytoma) or glioblastoma multiforme (GBM) constitutes the most frequent and malignant primary brain tumour. Current standard therapeutic strategies for their treatment are only palliative and survival after diagnosis is normally 6 to 14 months, 1 which is mainly due to the high invasiveness and proliferation rate of GBM. 2 In addition, the high frequency of molecular alterations (p53, IDH1 and IDH2 genes, RB, PTEN, unmethylated MGMT) renders GBM cells poorly sensitive to cytotoxic therapies and highly resistant to standard chemotherapy and radiotherapy. Among them, the most common genetic alteration associated with malignant glioma is the over-activation and/or overexpression of the epidermal growth factor receptor (EGFR, also referred to as ERBB1 or HER1), a wellknown oncoprotein belonging to HER superfamily of receptor tyrosine kinases together with ERBB2, ERBB3, and ERBB4 which transduce signaling through phosphatidylinositol 3-kinase (PI3K)/Akt and the ras-raf-mitogen-activated protein kinase (MAPK) pathways to control pleiotropic cellular processes, including cell differentiation, metabolism, proliferation, and survival. 3 When aberrant, these signaling leads to impaired apoptosis, and/or enhanced proliferation, angiogenesis, necrosis, and treatment refractoriness, suggesting a causative relationship between receptor dysregulation and the pathobiology of GBM. Among the many EGFR mutants described to date, the most common associated with GBM is DEGFR (also named EGFRvIII, or de2-7EGFR) 4 which arises through an in-frame deletion of 801 bp from the extracellular domain of EGFR and possesses ligand-independent constitutive (although low) tyrosine kinase activity. 5 Additionally, a low level of DEGFR autophosphorylation of DEGFR results in defective receptor internalization due to reduced interaction with Casitas B-lineage (Cbl) proteins, causing an increased stability of the receptor at the cell surface and amplified mitogenic effects. 6 Indeed activated EGFR also undergoes self-degradation via the endocytic pathway as an important mechanism for regulating the magnitude and duration of effector activity. 7 Because of the intratumoral heterogeneity of EGFR expression in GBM, many EGFRtargeted therapies in development or clinical trials such as TKIs, antibody-based therapies, and RNA-based therapies in GBM have been unsuccessful to date. 8 Consequently, novel therapeutic strategies, including alternative anti-EGFR approaches, for treating this disease are strongly required. Recent works have highlighted the pivotal role of some metabolic pathways in tumor development and progression. Malignant gliomas are highly dependent on the isoprenoid pathway for the synthesis of lipid moieties which are involved in the post-translational modification of intracellular signaling proteins critical for tumor growth and maintenance of the malignant phenotype, suggesting that the inhibition of this pathway may produce beneficial anticancer effects. Several classes of drugs targeting the isoprenoid pathway are already used to treat human diseases, including statins, bisphosphonates, and inhibitors of protein prenyl transferases. Notably, significant anti-tumor activity has been reported with concurrent lonafarnib, an oral farnesyl transferase inhibitor, radiation, and temozolomide, in a murine model of glioblastoma. 9 An emerging key modulator of the isoprenoid pathway seems to be the N6-isopentenyladenosine (i6A or iPA), an adenosine and isoprenoid derivative itself. iPA has been first discovered in plants, where it acts as a cytokinin, regulating plant cell growth and differentiation. In addition, iPA is present in mammalian cells bound to tRNA, in a reaction catalysed by isopentenyltransferase from adenosine and the intermediate isoprenoid dimethylallyldiphosphate (DMAPP) , an isomer of IPP. Free iPA, not bound to tRNA, has been found in yeast. iPA and some of its synthetic analogues have shown antiproliferative and proapoptotic effects against a broad variety of tumors in vitro and in vivo. [10] [11] [12] [13] Interest in the study of this compound has been reinforced by our previous experimental observations that iPA interferes with the growth of k-ras transformed thyroid cells (KiMol) xenograft tumors by inhibiting farnesyl pyrophosphate (FPPS) and protein prenylation, which suggests that this isoprenoid might be used for antineoplastic therapy. 11 More recently, it has been shown that iPA, phosphorylated by adenosine kinase (ADK) into 5'-iPA-monophosphate (iPAMP), activates the metabolic checkpoint AMP-activated protein kinase (AMPK), thus inhibiting in vitro and in a mouse model in vivo all the steps of the angiogenic processes.
14 This mimics the mechanism of action of the 5-aminoimidazole-4-carboxamide riboside (AICAR), a canonical pharmacological activator of AMPK which has been shown to retard growth of many cancers. In particular AICAR has been reported as a potent inhibitor of the growth of EGFRvIII-expressing GBM, 15 and has been shown to inhibit EGFR 1 breast cancer cells, with activation of AMPK and suppression of EGFR activity inducing cell death. Moreover, a direct interaction between AMPK and EGFR which contains sequences that are substrates for AMPK, has been recently documented. 16, 17 Accordingly, AMPK plays a role in dasanatib-induced EGFR degradation, critical for the induction of head and neck cancer cells apoptosis. In the present work we report for the first time the antitumor activity of iPA on glioma cells and its mechanism of action mediated primarily through AMPK-dependent EGFR degradation, by which cell growth and survival are affected.
Material and Methods

Reagents and Abs
N6-isopentenyladenosine (iPA), (Sigma-Aldrich, St. Louis, MO), was dissolved in DMSO and added to cell cultures at the indicated concentration. MG132 (Sigma-Aldrich St Louis, MO), a selective inhibitor of proteasome was dissolved in DMSO and added to cell cultures at the indicated concentration 1 hrs before the treatment with iPA. Compound C, a selective and reversible AMP-kinase inhibitor dissolved in DMSO was obtained from Calbiochem (San Diego, CA) and was added to cell cultures at the indicated concentration 1 hrs before the treatment with iPA5-Iodotubercidin (Itu), an adenosine kinase inhibitor, was obtained from Cayman (Ann Arbor, Michigan), was dissolved in ethanol, and then was
What's new?
A modest efficacy is achieved by treatment strategies targeting the aberrant signaling from EGFR in glioma, validating EGFR as a therapeutic target but motivating the development of improved anti-EGFR strategies. The isoprenoid pathway, frequently deregulated, is a promising target: as EGFR is highly dependent on the isoprenoid moieties for correct localization and signaling, its manipulation by isoprenoid-derivatives offers a new valid opportunity. Here, the authors report for the first time the antitumor activity of the isoprenoid derivative N6-isopentenyladenosine (iPA) on glioma cells and its action mechanism mediated primarily through AMPK-dependent EGFR degradation, by which cell growth and survival are affected.
added to cell cultures at the indicated concentration 1 hrs before the treatment with iPA. Human EGF was purchased from Peprotech (London, UK). z-VAD-fmk was obtained from R&D Systems (Minneapolis, MN). In fluorescence microscopy experiments rabbit polyclonal anti-human EGF Receptor (Abcam, Cambridge, UK) and Fluor V R 488 donkey anti-rabbit IgG secondary antibody (Molecular Probes V R -Invitrogen, Paisley, UK) were used. For western blot analysis the following antibodies were used: rabbit polyclonal anti-human b-actin were purchased from Abcam (Cambridge, UK), mouse monoclonal antihuman a-Tubulin from Sigma-Aldrich Inc. (St Luis, MO), rabbit polyclonal anti-human cleaved Caspase-3, rabbit polyclonal anti-human caspase-3, rabbit monoclonal anti human cleaved caspase-9, rabbit monoclonal anti-human caspase-9, rabbit monoclonal anti-human caspase-7, rabbit monoclonal anti-human cleaved caspase-7, rabbit monoclonal anti-human cleaved caspase-8, rabbit monoclonal anti-human Bad, rabbit monoclonal anti-human Bak, rabbit monoclonal anti-human Bim, rabbit monoclonal anti-human Bcl-2, rabbit monoclonal anti-human Bcl-xL, rabbit monoclonal anti-human phospho-EGF receptor (p-EGFR; Tyr1045), rabbit monoclonal antihuman phospho-EGF receptor (p-EGFR; Tyr1068), rabbit monoclonal anti-human phospho-EGF receptor, rabbit monoclonal anti-human EGF receptor, rabbit polyclonal antihuman phospho-STAT3 (p-STAT3; Tyr705), rabbit monoclonal anti-human p-Cbl, rabbit monoclonal anti-human STAT3, rabbit monoclonal anti-human AMPKa, rabbit monoclonal anti-human phospho-AMPKa-1 (p-AMPKa-1; Ser485), rabbit monoclonal anti-human cleaved PARP (Asp214), rabbit monoclonal anti-human PARP, rabbit monoclonal anti-human phospho-p44/42 MAPK (p-Erk1/2; Thr202/Tyr204), rabbit monoclonal anti-human p44/42 MAPK (Erk1/2), rabbit monoclonal anti-human PhosphoAkt (p-Akt; Ser473) and rabbit monoclonal anti-human Akt were purchased from Cell Signaling Technology (Danvers, MA), rabbit polyclonal p-Tyr Antibody (PY350) was purchased from Santa Cruz Biotechnology (Dallas, TX) Secondary HRP-linked goat anti-mouse or goat anti-rabbit IgG, were also purchased from Cell Signaling Technology (Danvers, MA).
Cells and clinical samples
Normal Human Astrocytes (NHA) are normal human cells derived from human brain tissue and were cultured in recommended medium AGM TM BulletKit TM (Lonza). The human glioma cell line U87MG was obtained from CLS Cell Lines Service GmbH (Eppelheim, Germany).
Small pieces of brain tissue containing tumor were collected at the time of craniotomy for tumor resection at the Neurosurgery Service of "G. Rummo" Medical Hospital (Benevento, Italy) and the Neurosurgery Service of "San Giovanni di Dio Ruggi d'Aragona" Medical Hospital (Salerno, Italy). The samples were divided into a portion immediately processed to generate primary tumor cell lines and a portion stored at 2808C for subsequent Western blot (WB) analysis. A second sample from each patient was also taken for clinical diagnosis performed by expert neuropathologists in accordance with the International Classification of CNS tumors drafted under the auspices of the World Health Organization (WHO). The tumors were diagnosed as astrocytoma (WHO grade I-III; n 5 3), glioma (WHO grade II, n 5 2) or glioblastoma multiforme (WHO grade IV; n 5 18). There were not significant differences by gender, or age between the different groups (Supporting Information Fig. 1 ). All tissue samples were collected in accordance with the ethical standards of the Institutional Committee (DEL. N8548 04/20/2007, April 3, 2013). The patients had been informed about the establishment of cellular models from their tumour and had given informed consent in written form. The preparation of adherent primary cultures of brain tumor cells (designated as GBMn) was conducted as reported elsewhere. 18 Human GBM cells U87MG was cultured in EMEM (Lonza) supplemented with 10% heat-inactivated fetal bovine serum (Euroclone), 1% L-glutamine, 1% antibiotic mixture, 1% sodium pyruvate, 1% non-essential aminoacids (Euroclone).
All cell cultures were maintained at 378C in humidified 5% CO2 atmosphere. synthesized BrdU-DNA was determined by an ELISA plate reader (ThermoScientific) at 450 nm. All experiments were performed in triplicate, and the relative cell growth was expressed as a percentage in comparison with the untreated control cells (100%).
Apoptosis analysis
Quantitative assessment of apoptosis of U87MG cells or NHA was analyzed by anti-human Annexin V (BioLegend, San Diego, CA, USA) and PI staining. Briefly, cells grown in 100-mm dishes for 24, 48 and 72 h in EMEM containing 2% FBS or in recommended medium AGM TM BulletKit TM (Lonza) were harvested with trypsin and washed in PBS. The cells were resuspended in Annexin V binding buffer (10 mM HEPES/NaOH, pH 7; 140 mM NaCl; and 2.5 mM CaCl 2 ) and stained with Annexin V-FITC for 20 min at room temperature (RT) and then with PI at RT for additional 15 min in the dark. The cells were acquired by flow cytometer within 1 h after staining. At least 10,000 events were collected, and the data were analyzed by Cell-Quest Pro software (Becton Dickinson, San Jose, CA).
Western blot (WB) analysis and assessment of ubiquitinylated EGFR
For analysis of protein levels cells were grown in p60 tissue culture plates at a density of 2 3 10 4 cells/cm 2 for 24 h.
Tumor cells were then incubated with vehicle, iPA, MG132, Compound C, Itu as indicated in the text. After incubation cells were washed with PBS, harvested and lysed in ice-cold RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-100, 0.5% deoxycholic acid, 10 mg/ml leupeptin, 2 mM phenylmethylsulfonyl fluoride, and 10 mg/ml aprotinin). Tumor pieces were disrupted for protein extraction by gentle homogenization (Potter-Elvehjem Pestle) in cold RIPA buffer. After removal of cell debris by centrifugation (14,500g for 20 min at 48C), the proteins were estimated and then analyzed using the protocol described elsewhere. 19 Levels of ubiquitinylated EGFR protein were assessed using the UbiQapture V R -Q Kit (Enzo Life Sciences, Farmingdale, NY), following the manufacturer's instructions.
Phospho-RTK array
Human phospho-receptor tyrosine kinase (RTK) arrays (R&D Systems) were used to determine changes in phosphorylation among 39 different RTK, according to the manufacturer's protocol. Isolated proteins (125 lg) from glioma cells U87MG treated for 18 h with iPA 10 lM, were incubated with RTK arrays. Pan-phospho-tyrosine antibodies conjugated to horseradish peroxidase were incubated with the arrays, detected using chemiluminescence and visualized using enhanced chemiluminescent substrate. Densitometric analysis was performed using Photoshop according to the manufacturer's instructions. Decreases in phosphorylation that were <10% were qualitatively excluded.
Mice experiments
We used U87MG cells in the tumor xenograft models because this cell line has been widely used due to their tumorigenicity in nude mice.
Athymic CD1-deficient nude mice were purchased from Charles River Laboratories (Sulzfeld, Germany). Female mice of 6 to 8 weeks old were used in all the experiments. The experiments were performed according to NIH guidelines, Guide for the care and Use of laboratory Animals. Mice were bred at Animal research Facility of Biogem scarl, Institute for Genetic Research ''Gaetano Salvatore'', (Ariano Irpino Avellino, Italy) in accordance with the Institutional Statement for the Use of Animals in cancer research.
U87 luciferase expressing glioblastoma cells (luc-U87) were furnished by Biogem scarl. Before the implant the cells were expanded, evaluated for contaminations and vitality, counted and resuspended in M199 medium. Cells were inoculated subcutaneously (s.c) in the right flank region at a concentration of 5 3 10 6 /100 ml/mouse. Treatments began 9 days after injection. The day before the first administration (day, 1) mice were subdivided in tumor volume (TV) homogeneous groups of treatment (N 5 10-12 each) in the following experimental groups: control (intraperitoneal injection of vehicle, three times a week for 4 weeks) and iPA (intraperitoneal administration of 50 lg/ mouse iPA, three times a week for 4 weeks). Mice were daily monitored for clinical signs and mortality. Body weight recordings were carried out two times a week. Tumor growth was monitored two times a week with a Mitutoyo caliper. The formula TV (mm 3 ) 5 [length (mm) 3 width (mm) 2 ]/2 were used, where the width and the length are the shortest and the longest diameters of each tumor, respectively. The end of the experiment was fixed at 6 weeks after the injection. After 41 days, at the end of experiment, all animals for each group were sacrificed by cervical dislocation. Explanted masses were weighted, photo recorded and processed for subsequent Western blot (WB) analysis.
Statistical analysis
Statistical analysis was performed in all the experiments shown by using the GraphPad prism 6.0 software for Windows (GraphPad software). For each type of assay or phenotypic analysis, data obtained from multiple experiments are calculated as mean 6 SD and analyzed for statistical significance using the two-tailed Student's t-test, for independent groups, or ANOVA followed by Bonferroni correction for multiple comparisons. p Values <0.05 were considered significant. *p < 0.05, **p < 0.01 and ***p < 0.001.
Results
Effects of iPA on DNA synthesis and viability in U87 glioma cells and normal human astrocytes
The glioma cell line U87 and normal human astrocytes (NHA cells) were cultured with increasing concentrations of iPA (0.3-20 mM) for 24, 48 and 72 h. As reported in Figure  1aA induced a dose and time-dependent inhibition of DNA synthesis in U87 cells. The IC50, as measured by inhibition of BrdU incorporation, was 7.5 mM at 48 h and 2.5 mM at 72 h of treatment. Of note, iPA did not elicited significant reduction of NHA proliferation, as the normal cell compartment of GBM cancer cells in the same experimental conditions (Fig. 1b) . In order to assess whether besides inhibition of DNA synthesis iPA was also able to induce apoptosis, we performed cell death analysis by Annexin-V and propidium iodide double staining (Fig. 1c) . We observed a dosedependent induction of apoptosis, resulting in the death of 20.1 6 2.4% of cells (p 0.001) after 48 h exposure at 5 mM iPA dose and of 38.9 6 7.2% (p 0.001) at 10 mM iPA. Interestingly, in control NHA cells, apoptotic events were barely detectable, suggesting the specificity of iPA pro-apoptotic effect in tumor cells (Fig. 1d) .
iPA inhibits the oncogenic AKT and STAT3 signaling and induces apoptosis, by caspase cascade activation through the intrinsic pathway Activation of AKT, ERK and STAT3 signaling is critical for glioma cell proliferation and survival. 20 Therefore, we determined by western blot the phosphorylation status of these proteins in iPA treated cells (Fig. 2a) . iPA (10 lM) significantly suppressed AKT-Ser 473 and STAT3-Tyr 705 phosphorylation in U87 cells. ERK phosphorylation displayed a biphasic course, being reduced by iPA at concentration ranging from 1 to 5 lM, and increased at 10 mM. Then we examined the expression of caspases and key proteins that play a pivotal role in apoptosis.iPA treatment (48 h) strongly induced caspase-9, caspase-3 and PARP cleavage in a concentration-dependent manner (Fig. 2b) , without affecting caspase 8. The expression of proapoptotic Bim, Bad and Bak proteins and the antiapoptotic Bcl-2 and Bcl-XL proteins was further examined to explore the mechanism of iPA-induced apoptosis. A remarkable increase of the levels of the three major Bim isoforms (Bim EL, L, S), which well correlates with the presence of the cleaved form of PARP and with the inactivation of AKT, and of BAD expression was accompanied by a decrease of Bcl-2 at the highest dose, whereas Bcl-XL expression was not affected (Fig. 2b) . The decreased expression of Bcl-2, a canonical transcriptional target of AKT, achieved with the highest dose of iPA, fits well with the observed inhibition of the AKT kinase, as well as the marked increase in the levels of the three major Bim isoforms (Bim EL, L, S) correlates with the presence of the cleaved form of PARP and with the inactivation of AKT. Changes in the proapoptotic Bad and Bak did also correlated with cell death upon iPA exposure (Fig. 2b) . As expected the 
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broad spectrum caspase inhibitor z-VAD-fmk completely inhibited caspase 3 activation and of course Bak expression in response to 24 h treatment with iPA (10 mM), corroborating its effects on intrinsic machinery of apoptosis and of induction of the caspase dependent cell death (Fig. 2c) .
iPA treatment induces regression of glioma in vivo
To evaluate iPA efficacy in vivo, we tested the drug on glioma tumor growth in a subcutaneous xenograft model using the highly tumorigenic U87 cells.
Twenty-four nude mice were injected s.c. with U87 cells in suspension. When tumors size reached approximately 4 to 6 mm in diameter, 12 mice were injected intraperitoneally with 50 mg iPA three times a week for 4 weeks, while 12 mice in control group received vehicle alone (PBS) (Fig. 2d) .
We observed that the mice in the iPA group had significantly smaller tumor sizes compared with the mice in the control group (day 31, 34, 37, and 41). Furthermore, we analyzed by Western blot the tumor lysates at the end of the experiment. Consistent with our in vitro observations, phosphorylation of STAT3 and ERK were downregulated by iPA treatment whereas cleaved caspase 3 was remarkably increased. Moreover, the anti-apoptotic protein Bcl-XL was clearly inhibited (Fig. 2e) . All the results corroborated an iPA anti-glioma effect also in the in vivo setting.
Pathway activation signature of iPA effects in human glioma: A role for EGFR It is well characterized that PI3K-AKT, STAT and Ras-MAPK (ERK) pathways, which regulate cellular growth, 6 /mouse U87 cells in suspension (100 ml). When tumor size reached approximately 4-6 mm in diameter mice were injected intraperitoneally with 50 mg iPA (full dots) or vehicle (open dots) three times a week for 4 weeks and tumors size were recorded (*p < 0.05, ****p < 0.001). E Western blot analysis of total and phosphorylated STAT, ERK, and total Bcl-XL, caspase-3 and cleaved caspase-3 in whole extracts from U87 tumor xenografts treated with or without iPA for 41 days. a-tubulin was used as control of protein loading. Two representative tumors for each treatment group are displayed.
proliferation, and survival, are downstream players of receptors tyrosine kinase (RTK). 21 Therefore we examined the phosphorylation status of 39 tyrosine-kinase receptors (TKR) by an antibody array-based assay (Fig. 3a) . Among all the detectable spots, iPA treatment downregulated or left unchanged the phosphorylation of all TKR except EGFR that resulted increased (Fig. 3b) . Because EGFR alterations are found in up to 60% of GBM in the clinic, promoting tumor growth and survival through persistent activation of signaling nertworks, (including ERK, STAT and AKT cascade) and metabolic reprogramming, 22 we decided to better investigate this aspect. The data of proteome analysis were confirmed in U87 cells by western blot analysis of EGFR phosphorylated on tyrosine. Consistent with the result obtained by the array, iPA significantly increased the EGFR phosphorylation on tyrosine at 18 h time point (Fig. 3c) . Although EGFR activation is usually associated with cell survival, it is well established that in some cells, activation of the EGFR by phosphorylation can also results in its degradation and cell death. Thus we aimed to delucidate the significance of iPAinduced EGFR phosphorylation and if EGFR degradation might have a role in iPA-induced cytotoxicity in glioma. In particular, EGFR phosphorylation at tyrosine 1068 is known to be associated with the activation status of the receptor, whereas phosphorylation at tyrosine 1045, a binding site for the E3 ubiquitin ligase cbl, is associated with ubiquitination and degradation of the receptor. 19, 23, 24 These events occur at early time points, so we analyzed by Western blot the levels of phosphorylation of EGFR-Y1045 and EGFR-Y1068 in U87 cells treated with iPA for 120 and 180 min (Fig. 3d) . Of note iPA induced phosphorylation of EGFR-Y1045, concomitantly decreasing phosphorylation of EGFR-Y1068.
iPA induces EGFR proteosome/lysosome-mediated degradation via phosphorylation and ubiquitination
In the light of the results obtained on the phosphorylation status of EGFR, later we investigated the possibility that iPAinduced ubiquitination and hence degradation of the receptor. We first assessed the level of ubiquitination of EGFR after exposure to iPA in U87MG cells. We observed increased EGFR ubiquitination in response to iPA treatment already at 3 h (Fig. 4a) . Additional evidence supporting the ubiquitination of the receptor was seen in immunoblot analysis reported in Figure 4b in which iPA action followed the well-established mechanism by which EGF binds to EGFR and stimulates the physiological internalization and degradation of the receptor. 23, 24 As expected, EGF-induced downregulation occurs as early as 6 min after treatment with a high dose (100 ng/ml). This is accompained by phosphorylation of EGFR in Y1045 residue and by a slight increase in the activation level of E3 ubiquitin ligase cbl (Fig. 4b) . At the same way, but at later time points (120 min) iPA was able to 
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induce phosphorylation of EGFR-Y1045, concomitantly increasing phosphorylation of cbl and slightly reducing EGFR expression. According to increased ubiquitination, in the following hours the total level of EGFR significantly decreased, as well as its downstream effectors including AKT and ERK (Fig. 4c) . The ubiquitination-mediated EGFR degradation induced by iPA was further supported by the counteracting effect of the proteasome/lysosome inhibitor MG132. MG132 pretreatment (10 lM, 4 h) prevented iPA-mediated EGFR degradation, causing an accumulation of ubiquitinylated form of the receptor, reverting the inhibitory effect on P-AKT and P-ERK (Fig. 4c) and counteracting the induction of apoptosis observed with iPA (Fig. 4d) . In immunofluorescence experiments shown in Figure 4e was found primarily on the plasma membrane in untreated cells. The location of a small amount of EGFR in lysosomes may be due to the physiological recycling of receptor. As expected, iPA induced a rapid EGFR internalization accompanied by its disappearance, which is prevented by MG132 pretreatment. This finding, together with the absence of co-localization of EGFR and the red-fluorescent dye of lysosomes lysotracker, may suggest a role for the proteasome pathway, rather than lysosomes in iPA-induced EGFR degradation, that need to be better dissected. However, irrespective of the exact mechanism, immunoblot analysis of amount of total EGFR at later time points, revealed that the effect of iPA on receptor loss persisted through 24, 48 and 72 h time points (Fig. 1f) .
iPA regulates EGFR expression through an AMP-activated kinase (AMPK)-dependent mechanism
Our recent demonstration that iPA can activate AMPactivated kinase (AMPK), 14 a potent inhibitor of the growth of EGFRvIII-expressing glioblastomas, 15 prompted us to investigate the role of AMPK in iPA-antiglioma effects. The treatment of U87 cells with iPA (10 lM, 1 h) resulted in increased AMPK activity, as documented by the increased phosphorylation of AMPK-a catalytic subunit, which is accompanied by an increased phosphorylation of EGFR on Y1045, an effect counteracted by co-treatment with the AMPK inhibitor compound C (5 lM) (Fig. 5a) . Furthermore, the increase in AMPK activity was completely reversed by 5-Itu pretreatment (30 nM), an inhibitor of adenosine kinase ADK which has been shown to convert iPA into iPAMP. 14 We observed that 5-Itu pretreatment reversed the phosphorylation of both EGFR and cbl induced by iPA at early time points (2 h) and later (4 h). Moreover, 5-Itu caused the complete rescue of iPA-induced EGFR degradation and inactivation of its downstream effectors, ERK and AKT (Fig. 5b) . All these results suggest that iPA must be phosphorylated into its iPAMP active form by ADK to exert its inhibitory and cytotoxic effects on glioma cells, through AMPK-mediated EGFR degradation (Fig. 5b) .
Analysis of sensitivity of primary glioma patient-derived cells to iPA treatment
Based on our results, cancer cells with higher levels of EGFR expression/activity should be more sensitive to iPA. To verify this hypothesis, we examined the expression of EGFR in 34 primary glioma samples, including grade II, III, and IV tumors from treatment-na€ ıve patients (Supporting Information Fig. 1 ). Accordingly to the literature, 25 western blot results showed that EGFR is commonly amplified and or overexpressed in most of primary GBM analyzed (16/26 of GBMIV) (Fig. 6a) . As control, EGFR levels did not show any apparent differences between normal human astrocyte and low grade tumors such as astrocytomas grade II and III. We then established primary cell lines from some fresh resectioned tumors of selected glioma patients. After verifying the expression of EGFR in the 11 established primary cell lines (Fig. 6b) , we moved to characterize their sensitivity to iPA treatment in order to test its efficacy in a more physiopathological context ex vivo. The patients-derived cells were treated with increasing concentration of iPA (0.3-20 mM) for 48 h. Here, as showed for three representative patients, iPA achieved a 50% growth inhibition (IC 50 ) at lower concentrations than in U87 cells (Fig. 1a) , that is 2 mM in GBM24 primary cell line and 0.45 mM in those derived from GBM39 and GBM50 tumors versus 7.5 mM in U87 (Fig. 6c) . However, a common molecular mechanism seems to be responsible for such effects. As shown, iPA (10 mM) inhibited the 
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phosphorylation of STAT3 and to a lesser extent of AKT, in all glioma cells either when the signaling operated constitutively either when EGFR was activated by EGF administration (100 ng/ml) (Fig. 6d) . In contrast, the unchanged ERK phosphorylation levels may be ascribed to the previously discussed biphasic effects of iPA for which the concentration of 10 mM, was responsible for ERK induction rather than inhibition.
Discussion
In the current study, we found that iPA, an end product of the mevalonate pathway with an isopentenyl chain linked to the nitrogen at position 6 of the purine base, induces apoptosis and growth inhibition in both cultured U87 cell line and in primary GBM patients-derived cells. The antitumor effects of iPA have already been reported in several tumors along with a direct antiangiogenic activity 14 and surprising immunomodulatory properties, 19, 26 both fundamental to counteract tumor growth and progression. Here we disclose a new anticancer mechanism of iPA specific for GBM tumor control. Indeed, our findings reveal that iPA causes EGFR downregulation through proteasome degradation, a key event which explains the dual activity of iPA on cancer cell proliferation and survival. First, iPA is responsible for the downregulation of the anti-apoptotic effector pAKT, leading to the reduction of prosurvival signals (Bcl-2 in vitro and Bcl-XL in vivo) the upregulation of pro-apoptotic proteins (Bim, Bad, Bak), caspase activation, PARP cleavage and apoptosis. This finding has a great therapeutic value considering the pro-survival microenvironment of GBM and the high levels of oncogenic BCL-XL. 27 Second, the inhibition of downstream STAT and ERK signaling, by receptor downregulation, may account for the synergistic control of proliferative status by iPA in GBM cells. Indeed, although we documented a biphasic action of iPA at later time points (24-48 h), in the light of the results on cell proliferation and apoptosis, the outcome of its effect on ERK cascade may be considered anti-tumorigenic. MEK-ERK pathway may not solely provide proliferation signals to malignancies, the central scientific rationale in developing MEK inhibitors for cancer therapy, but accumulating evidence now demonstrated that it contributes to the proper execution of cellular DNA damage response (DDR), a major pathway of tumor suppression. 28 Activation of ERK1/2 is indeed commonly induced in multiple cell lines by a variety of genotoxic agents. In T98G cells activation of ERK was observed in response to cisplatin and UV light and was shown to strongly promote apoptosis in these GBM cell line. 29 In this context, our finding are also in agreement with substantial evidence showing that cisplatin-induced cytotoxicity is critically dependent upon phosphorylation and subsequent degradation of EGFR in head and neck cancer cell lines HNSCC 30 and in MDA-MB-468 breast cancer and A431 epidermoid cell lines. [30] [31] [32] [33] A common characteristic of these cells is that they overexpress the EGFR, a feature that is also found in U87 glioma cells for which iPA resulted in massive apoptosis in vitro and significant tumor regression in vivo. Interestingly, this mechanism has also been demonstrated in response to several other cytotoxic chemotherapeutic agent now in clinical use. For example, EGFR depletion by the induction of E3 ubiquitin ligase c-Cbl contributes to the anti-cancer effects of HDAC inhibitors, including with panobinostat, in EGFR-mutant, TKI-sensitive lung cancer cells. 34 AUY922, an HSP90 inhibitor, causes degradation of HSP chaperones and their client proteins, including EGFR, and a phase I/II trial has been recently conducted to evaluate its synergy with erlotinib for patients with EGFR-mutant lung cancer, acquired resistance and disease progression during erlotinib treatment. 35 Downregulation of EGFR through lysosomal degradation, has also been shown to mediate the apoptosis induced by the Src inhibitor Dasatinib in head and neck squamous cell carcinoma 33 that may explain its efficacy in a phase I/II study in combination with erlotinib for nonsmall cell lung cancer. 36 Through the same mechanism, along a proteasome/lysosome-mediated pathway which was responsible for receptor degradation and its downstream signaling pathways inhibition, gemcitabine has been reported to induce cytotoxicity in head and neck cancer cells. 32 Here we described for iPA a more complex and precise mechanism of EGFR loss. EGFR degradation is initiated by receptor phosphorylation and ubiquitination, and proceeds along a proteosomal pathway. Downregulation of EGFR by iPA was evident as early as 4 hrs. The inability to observe a trafficking of the receptor to lysosomes upon iPA treatment may suggest the importance of the proteosomal rather than lysosomal activity in such effect. Consistent with this, the proteasome inhibitor MG132 prevented the degradation of EGFR induced by iPA and hence all the downstream molecular and biological events caused by receptor loss which interestingly, persisted through 72 h (Fig. 1f) . The finding that iPA increases the ubiquitination of EGFR, provides further support for the hypothesis that the isoprenoid compound increases EGFR degradation through the ubiquitin/proteasome pathway. Additional indirect evidence to support ubiquitination was seen in the immunoblot analysis of lysates. As reported elsewhere 24 a variable increase in the molecular weight of EGFR, seen as an "up-smearing" on immunoblots, is indicative of ubiquitination. Moreover, the increased phosphorylation of the E3 ubiquitin-ligase cbl, constitutes another proof of the ubiquitination and proteolytic processing. Looking for the mechanism of action of iPA, we analyzed iPA effect on earlier events in the degradation pathway. iPA specifically induced tyrosine phosphorylation at pY1045, reported to be essential for the stable association of EGFR with cbl, which then leads to ubiquitin binding and targeting of the receptor for degradation, while phosphorylation of EGFR at sites such as pY1068, which are important in downstream signaling, were decreased by iPA. These events occur at time points that precede major downregulation of total EGFR, specifically they occur as early as 120 min after treatments, lasting through 180 minutes and no longer present at 4 h, similar to the pathway established for EGF-induced physiological EGFR degradation when proliferation is completed. 37 However, a little temporal discrepancy between iPA and EGF-induced downregulation of EGFR does exist. EGFinduced downregulation occurs as early as 6 min after treatment, lasting through 60 min and no longer present at 24 h. The mechanism by which EGF binds to EGFR and stimulates internalization and degradation of the receptors is well characterized. 38 As regard to iPA, the delay in its action could be due to its necessary conversion by adenosine kinase (ADK) into the monophosphorylated active form which afterwards may target some intermediate molecular events that eventually affects EGFR internalization and/or ubiquitination, even if we cannot exclude a direct interaction with the EGFR. One possible mechanism for such indirect effect seems to be AMPK activation. We previously demonstrated that iPAMP activated the metabolic checkpoint AMPK, which recently has been reported to directly phosphorylate regulatory sequences and inhibit the activity of HER2 and EGFR tyrosine protein kinase in breast cancer. 16, 17 We highlighted that the block of ADK activity with its inhibitor 5-Itu prevented the molecular effects of iPA on U87MG cells (Fig. 5b) , clearly indicating that phosphorylation of iPA into iPAMP is essential for its biological activity, as previously suggested in other cell systems 39 and similar to the process described in plants. 40 As expected, iPA, behaving as an AMP mimetic, activated the key metabolic enzyme AMPK which may constitute a critical link with EGFR processing as, the AMPK inhibitor, compound C, significantly reduced iPA-induced tyrosine phosphorylation at pY1045 and finally the EGFR "upsmearing" on immunoblots, indicative of its ubiquitination. However, here the lack of the induction of tyrosine phosphorylation at pY1045 by AMPK, might be explained by the later kinetics analysis (24 hrs) to which this event is no longer present in our cellular model, too. AMPK has been already reported to play a role in dasanatib-induced EGFR
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degradation, critical for the induction of head and neck cancer cells apoptosis 17 and most importantly AMPK activation through AICAR, strongly inhibited the growth of GBM cells in vitro, with markedly enhanced efficacy in EGFR-activated tumor cells. 15 Consistent with this last observation, we observed that iPA is highly efficacious at blocking tumor cell growth across a panel of EGFR-overexpressing/activated primary GBM cells in which the constitutively operating signaling and to a much extent, that induced by the ligand EGF, sensitizes the primary cells to iPA action. This finding suggests the highly dependence of iPA cytotoxic effects from EGFR signaling in the GBM model and a potential therapeutic strategy for targeting gliomas and possibly other tumors with EGFR activating mutations or amplification.
Overall, even though more evidence and future studies focusing on the link between iPA-AMPK-EGFR are needed, our data suggest that iPA inhibits GBM cell growth and survival primarily through AMPK-dependent EGFR internalization and degradation. An additional proof of the existence of this axis is the intriguing finding that the markedly anti-proliferative efficacy of AICAR on EGFR-activated glioblastoma cell growth was mediated through inhibition of cholesterol and fatty acid synthesis 15 suggesting that AMPK is a critical link between EGFR-mediated signal transduction and cellular metabolism 41 which is in lane with the intrinsic ability of iPA to primarly modulate the isoprenoid pathway in physio-pathological conditions. In our work, iPA clearly displayed antiglioma action through AMPK-dependent mechanisms; however, we have to take into account that it may also elicit other effects, as demonstrated elsewhere. Indeed, iPA reduces the growth of xenograft tumors induced by k-ras transformed thyroid cells (KiMol) by inhibiting farnesyl pyrophosphate synthase (FPPS), a key enzyme of the isoprenoid biosynthetic pathway and protein prenylation, which are crucial events for the function and activity of EGFR and its downstream signaling. Prenylation is indeed required for the proper function and localization of several downstream critical mediators of the EGFR signaling cascade, including the Ras, Rho, and Rab families, which require farnesyl and geranylgeranyl post-translational modifications for their activity. 42 This is true for the small G-protein rab7 which critically affects the EGFR degradation by regulating endocytic trafficking from the late endosomes. 43 In this case the intracellular accumulation of internalized receptor may be responsible for cell death, as demonstrated by Hyatt and Ceresa in MDA-MB-468 cells where only intracellular receptors induce caspase-3 activity and the induction of apoptosis. 31 The impact of iPA could extend beyond an inhibitory action on prenylation also to other products of the mevalonate pathway. For example, dolichol is involved in the N-linked glycosylation of EGFR, which facilitates its proper conformation and efficient ligand binding and activation of EGFR. 44 These aspects need to be deeply dissected in further studies. Alternatively, the previously supposed eventual binding of iPA to EGFR receptor or its ability to interfere with proper ligand binding could be corroborated by its role as cytokinin and the relative ability to finely tune different processes of proliferation and functional differentiation in plant and humans. 19, 45 This lead us to hypothesize a fascinating role for iPA inside mammalian cells like an endogenous EGFR negative regulator not only as an important protective feedback mechanism when EGFR signaling goes awry like in GBM, as described for the leucin-rich repeats and immunoglobulin-like domains 1 (LRIG1) 46 but also as maintaining mechanism the overall tissue homeostasis. Also in this case further studies are required to test this intriguing hypothesis.
An aberrant signaling from EGFR is implicated in multiple cancer types by dysregulation, autocrine signaling, overexpression, and mutations. Strategies targeting it have been approved for clinical use; however a modest efficacy is achieved, validating EGFR as a therapeutic target but motivating the development of improved anti-EGFR strategies. Perhaps our findings concerning the EGFR phosphorylation and degradation as a determinant mechanism of iPA-induced cell death could be used to specifically target not only GBM but also other tumors highly dependent on EGFR signaling. As anticipated by preclinical response to iPA in primary glioma patient-derived cells, one would predict that cancer cells with higher levels of EGFR expression/activity would be most sensitive to EGFR degradation and hence anti-tumor effect. It has been suggested that, as a regulator of isoprenoid pathway, the mechanism of action of iPA might emulate that of the lovastatin and/or farnesyl-transferase inhibitor. The potential of this class of drugs, in particular lovastatin, to induce synergistic cytotoxicity in combination with EGFR-TKIs 47 which translated in disease stabilization in a phase I clinical trial of rosuvastatin and erlotinib for HNSCC treatment, 48, 49 constitute an additional proof of iPA antitumor efficacy through loss of EGFR levels. This new intriguing aspect, together with the consolidated pleiotropic effects of iPA on cancer growth and progression, 10-13 angiogenesis 14 and immune anti-tumor responses stimulation, 19, 26 open the way to a new class of molecules targeting RTKs and predictive compensatory/resistance mechanisms, that may provide alone or in combination with anti-EGFR therapies, a more favorable future for these types of targeted therapies in GBM. Indeed the ability of iPA to interfere with co-activation of other TRKs and GPI-linked receptors (IGFR1, MET, PDGFRa/b, uPAR) (Fig. 3a) gives an adjunct value to the pharmacological potential of this molecule. Moreover, the efficacy of anti-EGFR therapies in GBM is currently limited by the low penetrance of the available small molecules or antibodies through the blood brain barrier. 50 Eventhough a more suitable orthotopic glioma mouse model would definitively clarify the anti-glioma potential of iPA, the lipophilic nature of this isoprenoid derivative may suggest that it would be a more brain accessible compound. In conclusion, iPA efficacy reported both in vitro and in vivo (Fig. 2c) , its surprising activity also in patientsderived primary GBM cells that more accurately reflect the physiopathological context, the lack of cytotoxicity on healthy brain cells and its favorable anti-angiogenic and immunomodulatory properties, make it an interesting lead compound for the development of novel valid chemotherapeutic agents to achieve glioma destruction.
